Media stories about Onconova Therapeutics (NASDAQ:ONTX) have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Onconova Therapeutics earned a daily sentiment score of 0.34 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.6677604004779 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Onconova Therapeutics, Inc. (NASDAQ:ONTX) – Market Cap Secrets – Nasdaq Journal (nasdaqjournal.com)
- Low Wild stock to watch: Onconova Therapeutics, Inc. (ONTX) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Oversold Signal Stock: Onconova Therapeutics, Inc. (ONTX) – Nasdaq Chronicle (nasdaqchronicle.com)
- Onconova Therapeutics, Inc. (ONTX) locked -39.89% below … – The Stocks News (press release) (thestocksnews.com)
- Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American … – GlobeNewswire (press release) (globenewswire.com)
Several equities research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $7.50 price target (up previously from $6.00) on shares of Onconova Therapeutics in a research report on Thursday, March 1st. Zacks Investment Research upgraded shares of Onconova Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Maxim Group restated a “hold” rating on shares of Onconova Therapeutics in a research report on Thursday, March 8th. Finally, ValuEngine upgraded shares of Onconova Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $8.00.
Shares of ONTX stock traded down $0.03 on Wednesday, reaching $0.97. 426,460 shares of the company traded hands, compared to its average volume of 516,821. Onconova Therapeutics has a 12 month low of $0.95 and a 12 month high of $3.88. The company has a market capitalization of $20.08, a PE ratio of -0.34 and a beta of 0.22.
Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.10. Onconova Therapeutics had a negative net margin of 3,061.37% and a negative return on equity of 558.97%. The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.31 million. sell-side analysts expect that Onconova Therapeutics will post -1.41 EPS for the current year.
In other news, major shareholder 683 Capital Management, Llc acquired 200,000 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were acquired at an average price of $1.04 per share, for a total transaction of $208,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.30% of the company’s stock.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.